A phase Ib study of oral panobinostat (LBH589) administered with 5-azacitidine (5-Aza) in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
2010 ◽
Vol 28
(15_suppl)
◽
pp. TPS282-TPS282
2019 ◽
Vol 19
(5)
◽
pp. 264-274.e4
◽
2016 ◽
Vol 209
(7-8)
◽
pp. 313-320
◽
2020 ◽
Vol 20
◽
pp. S191-S192